ReviewNeuro-oncology advances2025
Biomarkers of immunotherapy response in neuro-oncology.
Review in Neuro-oncology advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Human biomarker navigator.iMeta · 2026Review
- Immune checkpoint crosstalk between LAG-3 and CD39/CD73 in glioblastoma: dual-pathway regulation of metabolic exhaustion and therapeutic reversal strategies.Journal of the Egyptian National Cancer Institute · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While immunotherapy has shown significant promise for many cancers, its translation into the treatment of brain tumors has been limited. While several immunotherapy trials have been negative in brain cancer, these studies have identified a subset of responders which has generated considerable excitement for the future of the field. In this review, we summarize promising immunotherapy response biomarkers for CNS tumors with a focus on brain metastases, glioblastoma, and meningioma. The potential value of genomic, transcriptomic, cellular, proteomic, radiologic, and liquid biopsy approaches are discussed in a tumor-specific fashion. We emphasize the need to validate and expand upon each of these purported biomarkers. Disease-specific immunotherapy response biomarkers may potentially lead to more efficacious clinical trial designs, ultimately leading to new treatment options for a subset of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.